MCID: LYM118
MIFTS: 69

Lymphoma

Categories: Cancer diseases, Immune diseases, Neuronal diseases, Eye diseases

Aliases & Classifications for Lymphoma

Summaries for Lymphoma

MedlinePlus : 41 lymphoma is a cancer of a part of the immune system called the lymph system. there are many types of lymphoma. one type is hodgkin disease. the rest are called non-hodgkin lymphomas. non-hodgkin lymphomas begin when a type of white blood cell, called a t cell or b cell, becomes abnormal. the cell divides again and again, making more and more abnormal cells. these abnormal cells can spread to almost any other part of the body. most of the time, doctors don't know why a person gets non-hodgkin lymphoma. you are at increased risk if you have a weakened immune system or have certain types of infections. non-hodgkin lymphoma can cause many symptoms, such as swollen, painless lymph nodes in the neck, armpits or groin unexplained weight loss fever soaking night sweats coughing, trouble breathing or chest pain weakness and tiredness that don't go away pain, swelling or a feeling of fullness in the abdomen your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. targeted therapy uses substances that attack cancer cells without harming normal cells. biologic therapy boosts your body's own ability to fight cancer. if you don't have symptoms, you may not need treatment right away. this is called watchful waiting. nih: national cancer institute

MalaCards based summary : Lymphoma, also known as lymphoid neoplasm, is related to lymphoma, malt, somatic and folliculotropic mycosis fungoides. An important gene associated with Lymphoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs Adcetris and Arranon have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and cellular

Disease Ontology : 12 A hematologic cancer that affects lymphocytes that reside in the lymphatic system and in blood-forming organs.

Wikipedia : 72 Lymphoma is a group of blood cell tumors that develop from lymphocytes (a type of white blood cell). The... more...

Related Diseases for Lymphoma

Diseases in the Lymphoma family:

Adult Lymphoma Eye Lymphoma

Diseases related to Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1292)
id Related Disease Score Top Affiliating Genes
1 lymphoma, malt, somatic 34.4 BCL10 BCL2 BCL6 CCND1 CXCR5 MALT1
2 folliculotropic mycosis fungoides 31.6 BCL10 MALT1
3 nasopharyngeal carcinoma 30.1 ATM BAX BCL2
4 pulmonary hypertension 29.9 BAX BCL2
5 follicular lymphoma 12.4
6 hodgkin lymphoma 12.4
7 burkitt lymphoma 12.3
8 primary central nervous system lymphoma 12.3
9 mantle cell lymphoma 12.3
10 anaplastic large cell lymphoma 12.3
11 b-cell lymphomas 12.3
12 lymphoma, non-hodgkin 12.2
13 diffuse large b-cell lymphoma 12.2
14 plasmablastic lymphoma 12.2
15 gastric lymphoma 12.2
16 thyroid lymphoma 12.1
17 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 12.1
18 gray zone lymphoma 12.1
19 primary effusion lymphoma 12.1
20 intraocular lymphoma 12.1
21 lymphoblastic lymphoma 12.1
22 extranodal nasal nk/t cell lymphoma 12.1
23 myeloid and lymphoid neoplasms associated with fgfr1 abnormalities 12.1
24 splenic marginal zone lymphoma 12.1
25 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 12.1
26 cutaneous t cell lymphoma 12.1
27 marginal zone b-cell lymphoma 12.1
28 primary cutaneous follicle center lymphoma 12.0
29 composite lymphoma 12.0
30 follicular lymphoma 1 12.0
31 t-cell/histiocyte rich large b cell lymphoma 12.0
32 bone lymphoma 12.0
33 lymphoplasmacytic lymphoma 12.0
34 central nervous system lymphoma 12.0
35 orbital lymphoma 12.0
36 angioimmunoblastic t-cell lymphoma 11.9
37 peripheral t-cell lymphoma 11.9
38 enteropathy-associated t-cell lymphoma 11.9
39 hepatosplenic t-cell lymphoma 11.9
40 primary mediastinal large b-cell lymphoma 11.9
41 subcutaneous panniculitis-like t-cell lymphoma 11.9
42 myeloid/lymphoid neoplasm associated with pdgfrb rearrangement 11.9
43 myeloid/lymphoid neoplasm associated with pdgfra rearrangement 11.9
44 myeloid and lymphoid neoplasm with fgfr1 abnormalities 11.9
45 intravascular large b-cell lymphoma 11.9
46 relapsed/refractory diffuse large b-cell lymphoma 11.8
47 adult t-cell leukemia 11.8
48 alk-positive anaplastic large cell lymphoma 11.8
49 primary cutaneous peripheral t-cell lymphoma not otherwise specified 11.8
50 primary cutaneous aggressive epidermotropic cd8+ t-cell lymphoma 11.8

Graphical network of the top 20 diseases related to Lymphoma:



Diseases related to Lymphoma

Symptoms & Phenotypes for Lymphoma

GenomeRNAi Phenotypes related to Lymphoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.33 CTAGE1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.33 CTAGE1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.33 CTAGE1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.33 ATM
5 Increased shRNA abundance (Z-score > 2) GR00366-A-106 10.33 BCL2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.33 ATM
7 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.33 ATM
8 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.33 CTAGE1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.33 BCL2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.33 ATM BCL2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.33 BCL7C
12 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.33 CTAGE1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.33 BCL7C
14 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.33 ATM
15 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.33 ATM
16 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.33 CTAGE1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-159 10.33 BCL2 BCL7C ATM CTAGE1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.33 ATM
19 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.33 CTAGE1 BCL2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.33 CTAGE1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.33 BCL2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.33 BCL2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-2 10.33 BCL7C
24 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.33 BCL2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.33 ATM CTAGE1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-215 10.33 ATM
27 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.33 BCL7C
28 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.33 CTAGE1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10.33 BCL2
30 Increased shRNA abundance (Z-score > 2) GR00366-A-4 10.33 CTAGE1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-41 10.33 ATM
32 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.33 CTAGE1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.33 BCL7C
34 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.33 BCL2
35 Increased shRNA abundance (Z-score > 2) GR00366-A-76 10.33 CTAGE1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-8 10.33 ATM
37 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.33 ATM
38 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.33 ATM BCL2
39 Increased shRNA abundance (Z-score > 2) GR00366-A-88 10.33 BCL2
40 Increased shRNA abundance (Z-score > 2) GR00366-A-96 10.33 BCL2
41 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 BCL10 BCL2 MALT1 ATM BAX
42 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 BCL10 BCL2 CCND1 MALT1 MYC ATM

MGI Mouse Phenotypes related to Lymphoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.06 BCL6 CCND1 CXCR5 MYC TIAM1 ATM
2 endocrine/exocrine gland MP:0005379 9.96 ALK ATM BAX BCL10 BCL11A BCL11B
3 hematopoietic system MP:0005397 9.93 MYC ATM BAX BCL10 BCL11A BCL11B
4 immune system MP:0005387 9.73 ATM BAX BCL10 BCL11A BCL11B BCL2
5 neoplasm MP:0002006 9.23 ALK ATM BAX BCL11B BCL2 CCND1

Drugs & Therapeutics for Lymphoma

FDA approved drugs:

(show all 27)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Adcetris 17 46 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
2
Arranon 17 46 NELARABINE GlaxoSmithKline October 2005
3
Arzerra 17 46 OFATUMUMAB GlaxoSmithKline October 2009
4
Beleodaq 17 46 BELINOSTAT Spectrum Pharmaceuticals July 2014
5
Bexxar 17 46 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
6
Busulfex 17 46 BUSULFAN Orphan Medical February 1999
7
Elitek 17 46 RASBURICASE sanofi-aventis October 2009
8
Elliotts B Solution 17 CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE Orphan Medical October 1996
9
Folotyn 17 46 PRALATREXATE Allos Therapeutics September 2009
10
Imbruvica 17 46 IBRUTINIB Pharmacyclics November of 2013/February 2014
11
Intron A 17 46 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
12
Istodax 17 46 ROMIDEPSIN Gloucester Pharmaceuticals November 2009
13
Kyprolis 17 46 CARFILZOMIB Onyx Pharmaceuticals July 2012
14
Mozobil 17 46 PLERIXAFOR Genzyme December 2008
15
Neumega 17 OPRELVEKIN Genetics Institute November 1997
16
Revlimid 17 46 LENALIDOMIDE Celgene June 2013
17
Rituxan 17 46 RITUXIMAB Biogen IDEC, Genentech November 1997
18
Targretin 17 46 bexarotene VALEANT LUXEMBOURG 12/29/1999
19
Treanda 17 46 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
20
UVADEX 17 METHOXSALEN Therakos February 1999
21
Valchlor 17 MECHLORETHAMINE HYDROCHLORIDE Ceptaris Therapeutics August 2013
22
Velcade 17 46 BORTEZOMIB Millennium Pharmaceuticals May 2003
23
Xalkori 17 46 CRIZOTINIB Pfizer August of 2011
24
Zevalin 17 46 IBRITUMOMAB TIUXETAN Biogen IDEC February 2002
25
Zydelig 17 46 IDELALISIB Gilead July 2014
26
Zykadia 17 46 CERITINIB Novartis April 2014
27
Alecensa 17 ALECTINIB HYDROCHLORIDE Roche December 2015

Drugs for Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 949)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
3
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
5
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 3778-73-2 3690
6
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
7
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2068-78-2, 57-22-7 5978
8
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
9
Teniposide Approved Phase 4,Phase 3,Phase 2,Phase 1 29767-20-2 34698
10
Aprepitant Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 170729-80-3 151165 6918365
11
Fosaprepitant Approved Phase 4,Phase 2,Phase 1,Early Phase 1 172673-20-0 219090
12
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2 26787-78-0 33613 2171
13
Clarithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1 81103-11-9 84029
14
Metronidazole Approved Phase 4,Phase 3,Phase 2 443-48-1 4173
15
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 58957-92-9 42890
16
Asparaginase Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 9015-68-3
17
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 23214-92-8 31703
18
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
19
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 130167-69-0
20
Cladribine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 4291-63-8 20279
21
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-81-3 30323
22
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
23
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
24
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
25
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1 154-42-7 2723601
26
Vindesine Approved Phase 4,Phase 3,Phase 2,Phase 1 59917-39-4, 53643-48-4 40839
27
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
28
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
29
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
30
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
31
Denileukin diftitox Approved, Investigational Phase 4,Phase 2,Phase 1 173146-27-5
32
Bexarotene Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 153559-49-0 82146
33
Vidarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 24356-66-9 32326 21704
34
Entecavir Approved, Investigational Phase 4,Phase 2 142217-69-4 153941
35
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 5754 657311
36
Methoxsalen Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 298-81-7 4114
37
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 148-82-3 4053 460612
38
Granisetron Approved, Investigational Phase 4,Phase 2 109889-09-0 3510
39
Palonosetron Approved, Investigational Phase 4,Phase 2 135729-61-2, 119904-90-4, 135729-56-5 148211
40
Amifostine Approved, Investigational Phase 4,Phase 2,Phase 1 20537-88-6 2141
41 Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
42
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 55-98-1 2478
43
Dopamine Approved Phase 4,Phase 3 51-61-6, 62-31-7 681
44
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 65271-80-9 4212
45
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
46
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 56420-45-2 41867
47
Mechlorethamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-75-2 4033
48
Mesna Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 3375-50-6 598
49
Bleomycin Approved Phase 4,Phase 3,Phase 2,Phase 1 11056-06-7 5360373
50
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 4342-03-4 5351166

Interventional clinical trials:

(show top 50) (show all 6051)

id Name Status NCT ID Phase Drugs
1 Lymphoma in the Orbit Unknown status NCT01302912 Phase 4
2 Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old. Unknown status NCT00429065 Phase 4 Rituximab
3 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
4 ATG Could Improve the Outcome Of Hematopoietic Stem Cell Transplant in Patients With Highly Aggressive T Cell Tumors Unknown status NCT02290132 Phase 4 Rabbit Anti-human Thymocyte Globulin (ATG)
5 Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
6 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
7 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
8 HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
9 Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
10 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4 PEG-asparaginase
11 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
12 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
13 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
14 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
15 An Observational Study of Lymphoma in Patients With Rheumatoid Arthritis or Crohn's Disease. Completed NCT00440817 Phase 4
16 Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America Completed NCT02559583 Phase 4
17 Observational Study on the Occurrence of Hepatosplenic T-cell Lymphoma in Patients of Netherlands Completed NCT00731536 Phase 4
18 Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma Completed NCT00168727 Phase 4 ibritumomab tiuxetan (Zevalin®)
19 Treatment of Peripheral T-cell Lymphoma Completed NCT01664975 Phase 4 GDPT regimen;CHOP regimen
20 Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) Completed NCT00211198 Phase 4 ONTAK (denileukin difitox, DAB389IL-2)
21 PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy Completed NCT02805218 Phase 4 PEG-rhG-CSF
22 Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) Completed NCT01007448 Phase 4 bexarotene;bexarotene
23 MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
24 German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
25 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
26 Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma Patients Completed NCT02108444 Phase 4
27 Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms Completed NCT01164475 Phase 4 Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor
28 Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) Completed NCT00153530 Phase 4 methotrexate
29 Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma Completed NCT01124526 Phase 4 Rituximab Fludarabine Cyclophosphamide
30 Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B Completed NCT00926757 Phase 4 Entecavir prophylaxis;Therapeutic entecavir
31 Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma Completed NCT01569724 Phase 4
32 Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients Completed NCT00050999 Phase 4 ONTAK
33 An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) Completed NCT02782845 Phase 4 Chemotherapy;Immunochemotherapy;Pegfilgrastim
34 LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
35 Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Completed NCT00051012 Phase 4 ONTAK
36 Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma Completed NCT00090038 Phase 4 rituximab
37 Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy Completed NCT00230217 Phase 4 Rasburicase (SR29142)
38 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
39 Prevention of CHOP-induced Chronic Cardiotoxicity Completed NCT00162955 Phase 4 Valsartan
40 Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A Completed NCT00221039 Phase 4 Methoxsalen+ECP
41 Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Completed NCT01418430 Phase 4 CHOP-daclizumab
42 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
43 Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia Completed NCT01374373 Phase 4
44 Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy Completed NCT00524407 Phase 4 Epoetin alfa
45 Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture Completed NCT00808171 Phase 4 Livopan;Livopan;EMLA
46 ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
47 DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor Completed NCT00029523 Phase 4 Intrathecal (injected into the spinal fluid) DepoCyt;Intrathecal methotrexate;Intrathecal cytarabine (also known as ara-C)
48 AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors Completed NCT00415103 Phase 4 Aprepitant;Palonosetron;Granisetron
49 Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients Completed NCT00195533 Phase 4 piperacillin-tazobactam;glycopeptide
50 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)

Search NIH Clinical Center for Lymphoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: lymphoma

Genetic Tests for Lymphoma

Genetic tests related to Lymphoma:

id Genetic test Affiliating Genes
1 Lymphoma 29

Anatomical Context for Lymphoma

MalaCards organs/tissues related to Lymphoma:

39
B Cells, T Cells, Bone, Bone Marrow, Breast, Lung, Myeloid

Publications for Lymphoma

Articles related to Lymphoma:

(show top 50) (show all 22921)
id Title Authors Year
1
Loss of CD3 and TCRI^I' expression in a relapsed hepatosplenic T-cell lymphoma. ( 28573906 )
2018
2
Burkitt lymphoma and diffuse large B-cell lymphoma: a unique case of a composite lymphoma of different clonal origin. ( 28583033 )
2018
3
Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy. ( 26968188 )
2017
4
Primary cutaneous anaplastic large cell lymphoma with intralymphatic involvement associated with chronic lymphedema. ( 28337783 )
2017
5
Role of Radiation Therapy in the Treatment of Hodgkin Lymphoma. ( 28497317 )
2017
6
Predominance of CD4+ T Cells in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma and Identification of a Subset of Patients With Peripheral B-Cell Lymphopenia. ( 28575178 )
2017
7
Human immunodeficiency virus-negative plasmablastic lymphoma: A case report and literature review. ( 28207555 )
2017
8
Chemotherapy during Pregnancy: Cases of Hodgkin's and Non-Hodgkin's Lymphoma, Chronic Myeloid Leukemia, Breast Cancer, Nasopharyngeal Cancer, and Choriocarcinoma. ( 28700986 )
2017
9
The drive to generate multiple forms of oncogenic cyclin D1 transcripts in mantle cell lymphoma. ( 28503306 )
2017
10
Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas. ( 28791403 )
2017
11
Lacrimal gland and extensive subcutaneous tissue involvement by mantle cell lymphoma. ( 28860327 )
2017
12
Unilateral lung infiltrate: A rare form of presentation of primary pulmonary lymphoma. ( 28757282 )
2017
13
AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair. ( 28884410 )
2017
14
Angioimmunoblastic T-cell Lymphoma Associated with IgA Nephropathy. ( 28050005 )
2017
15
Prognostic Impact of MUM1/IRF4 Expression in Burkitt Lymphoma (BL): A Reappraisal of 88 BL Patients in Japan. ( 28079574 )
2017
16
Immunophenotype Expression Change From CD52+ to CD52- on Erythrodermic Peripheral T-cell Lymphoma, Not Otherwise Specified After Treatment With Alemtuzumab. ( 28937435 )
2017
17
Questioning the value of routine imaging for patients with mantle cell lymphoma in first remission. ( 28828884 )
2017
18
Splenic marginal zone lymphoma complicated by cold agglutinin disease. ( 28321090 )
2017
19
Bariatric Implant-Associated Anaplastic Large-Cell Lymphoma. ( 28945505 )
2017
20
PD-1 Blockade in Mediastinal Gray-Zone Lymphoma. ( 28679093 )
2017
21
T Cell Histiocyte Rich Large B Cell Lymphoma Presenting as Hemophagocytic Lymphohistiocytosis: An Uncommon Presentation of a Rare Disease. ( 28912991 )
2017
22
Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma. ( 28911093 )
2017
23
IL-4/CXCL12 loop is a key regulator of lymphoid stroma function in follicular lymphoma. ( 28202459 )
2017
24
Syringotropic Mycosis Fungoides: A Rare Form of Cutaneous T-cell Lymphoma Enabling a Histopathologic "Sigh of Relief." ( 28692463 )
2017
25
Philadelphia chromosome-positive B-lymphoblastic lymphoma involving the genitourinary system and bone at initial diagnosis and relapse. ( 28935645 )
2017
26
Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1. ( 28388555 )
2017
27
Primary Breast Lymphoma in the United States: 1975-2013. ( 28376147 )
2017
28
Recommendations for Clinical Trial Development in Follicular Lymphoma. ( 28040699 )
2017
29
Lymphoplasmacytic Lymphoma Presenting with Diarrhea and Joint Pain Which was Successfully Diagnosed by an MYD88 Mutation Analysis. ( 28381754 )
2017
30
Cardiac Tamponade as Initial Presentation of Angioimmunoblastic T-Cell Lymphoma. ( 28481741 )
2017
31
Role of core needle biopsy in primary breast lymphoma. ( 28510806 )
2017
32
An autopsy of intravascular large B-cell lymphoma with hemophagocytic syndrome. ( 28515953 )
2017
33
Usefulness of Flow Cytometry in Diagnosis of IgG4-Related Ophthalmic Disease and Extranodal Marginal Zone B-Cell Lymphoma of the Ocular Adnexa. ( 28870925 )
2017
34
Targeting non-Hodgkin Lymphoma with Blinatumomab. ( 28532177 )
2017
35
The BTK inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on the NF-I_B mutational status. ( 28838994 )
2017
36
Age and geographic patterns of Plasmodium falciparum malaria infection in a representative sample of children living in Burkitt lymphoma-endemic areas of northern Uganda. ( 28320389 )
2017
37
Pathways towards indolent B-cell lymphoma - Etiology and therapeutic strategies. ( 28802906 )
2017
38
BRAF (V600E) expression in histiocytic sarcoma associated with splenic marginal zone lymphoma: a case report. ( 28376906 )
2017
39
A Case of Type II Enteropathy-Associated T-Cell Lymphoma in a Patient With Ulcerative Colitis. ( 28572650 )
2017
40
B-cell lymphoma 2 inhibitor ABT-737 induces Beclin1- and reactive oxygen species-dependent autophagy in Adriamycin-resistant human hepatocellular carcinoma cells. ( 28351336 )
2017
41
Detection of the circulating tumor DNAs in angioimmunoblastic T- cell lymphoma. ( 28634614 )
2017
42
Italian real life experience with brentuximab vedotin: results of a large observational study on 40 relapsed/refractory systemic anaplastic large cell lymphoma. ( 28775121 )
2017
43
Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score. ( 28068241 )
2017
44
Positron Emission Tomography-Based Assessment of Metabolic Tumor Volume Predicts Survival after Autologous Hematopoietic Cell Transplantation for Hodgkin Lymphoma. ( 28942016 )
2017
45
A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. ( 28103725 )
2017
46
Quercetin induces apoptosis and autophagy in primary effusion lymphoma cells by inhibiting PI3K/AKT/mTOR and STAT3 signaling pathways. ( 28092744 )
2017
47
Current management of primary central nervous system lymphoma. ( 28841800 )
2017
48
Pulmonary Intravascular Large B-cell Lymphoma (IVLBCL) Disguised as an Asthma Exacerbation in a Patient with Asthma. ( 28717087 )
2017
49
A case of intravascular large B cell lymphoma presenting as nodular goiter. ( 28841887 )
2017
50
Numerous Ontogenetic Roads to Mantle Cell Lymphoma: Immunogenetic and Immunohistochemical Evidence. ( 28457696 )
2017